Editorial Contributor

Irl B. Hirsch, MD


Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition
University of Washington School of Medicine 

Dr. Hirsch is a professor of medicine and holds the Diabetes Treatment and Teaching Chair at the University of Washington School of Medicine in Seattle. He graduated from medical school at the University of Missouri, performed his internal medicine training at the University of Miami and Mt. Sinai Medical Center in Miami Beach, and completed his endocrinology fellowship at Washington University in St. Louis.

Dr. Hirsch has been interested in new technologies for the treatment of diabetes, particularly those involved in the use of insulin therapy. He has also been interested in the mechanisms of how insulin co-modulates inflammation with glucose and how this results in improvements in outcomes, particularly of hospitalized patients. The management of hyperglycemia in the hospital has been an interest of Dr. Hirsch for over 25 years. He has been involved in numerous research studies examining novel insulins continuous glucose monitoring, and more recently the artificial pancreas project. He has been involved in many of the key studies that have impacted diabetes treatments today: the DCCT, ACCORD, ADOPT, and ORIGIN. He is currently the co-PI for FLAT-SUGAR..

Dr. Hirsch is also interested in the use of computers in diabetes data management, and how pattern recognition can be used to improve diabetes control, in addition to how glycemic variability noted on glucose meter downloads may be an independent risk for microvascular complications. He has a very active clinical practice of which 80 percent of patients have type 1 diabetes. He has authored over 150 papers including reviews of insulin in the New England Journal of Medicine and JAMA, 40 editorials, numerous book chapters, and four books, written for patients and physicians. He is the past editor-in-chief of both DOC News and Clinical Diabetes, and recently completed his sixth year of the ABIM Subspecialty Board of Endocrinology, Metabolism, and Diabetes.